Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease

Inclusion criteria, participants with AVP-D: * AVP-D diagnosis * Age 7 to 21 years * Stable pituitary hormone replacement (no change in dose of hormone replacement in 4 weeks prior to baseline) * If on estrogen/progestin, participants agree to stop for at least 6 weeks prior to Main study visits * English language proficiency Inclusion criteria, PD: * Pituitary disease diagnosis * Age 7 to 21 years * Eligible participants are not required to be on hormone replacement for pituitary deficiencies. If receiving pituitary hormone replacement, no change in dose in 4 weeks prior to baseline) * If on estrogen/progestin, participants agree to stop for at least 6 weeks prior to Main study visits * English language proficiency Exclusion criteria for participants with PD • Current AVP-D diagnosis or desmopressin use Exclusion criteria for all participants: * History of pulmonary embolism or unprovoked deep venous thrombosis * History of breast/endometrial cancer as well as current therapies on estrogen modulators/blockers (i.e., tamoxifen, raloxifene, aromatase inhibitors) * History of ischemic stroke, transient ischemic attack, myocardial infarction, angina pectoris, or peripheral arterial disease * Pregnancy or breastfeeding within the last 8 weeks * History of stage 3 chronic kidney disease or cirrhosis * Active tobacco smoking or nicotine use * Psychosis or active suicidality * Known genetic cause of vasopressin deficiency. * Any significant illness or condition that the investigator determines could interfere with study participation, data collection or safety.